SK Bioscience, GSK Initiate Phase 3 Trial Of COVID-19 Vaccine Candidate

SK bioscience and GlaxoSmithKline plc (GSK.L,GSK) said Tuesday that they have initiated a phase 3 clinical study of SK's COVID-19 vaccine candidate, GBP510, in combination with GSK's pandemic adjuvant following positive interim phase 1/2 results.

The trial will enroll about 4,000 participants from a range of countries and will aim to evaluate GBP510's safety and immunogenicity compared to an active comparator - the AstraZeneca/Oxford University COVID-19 vaccine.

The study will be one of the first global Phase 3 trials to compare two different COVID-19 vaccine candidates, GlaxoSmithKline said in a statement.

The interim Phase 1/2 data showed that all participants who received the adjuvanted vaccine candidate developed strong neutralizing antibody responses, demonstrating a 100% seroconversion rate. Neutralizing antibody titres were between five and a maximum of eight times higher compared to sera from people recovered from COVID-19. No safety concerns have been identified to date in the ongoing study.

The company expects results from the phase 3 study in the first half of 2022 after which, subject to positive results and regulatory approval, the vaccine is expected to be supplied at scale worldwide through the COVAX facility.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Apple announced that Apple News will be extending its local news offering to three additional cities in the United States to offer local news experience to readers. The service will now be provided for Charlotte, Miami, and Washington, D.C. The local news experience for each city is curated by Apple News editors to provide coverage of topics of importance for local communities. Automaker General Motors Co. (GM) on Wednesday reported third-quarter net income attributable to shareholders of $2.42 billion or $1.62 per share, lower than $4.05 billion or $2.78 per share in the prior-year quarter. Excluding items, adjusted net income for the quarter was $1.52 per share, compared... Boeing on Wednesday reported a loss for the first quarter that sharply narrowed from last year, reflecting an 8 percent increase in revenues on higher commercial airplanes and services volumes. However, core loss per share and quarterly revenues came in below analysts' expectations. Looking ahead, the airplane maker said supply chain capacity and global trade will be key drivers of the industry.
Follow RTT